Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a targeted nerve procedure ease Post-Stroke shoulder pain?

NCT ID NCT07753759

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests two ultrasound-guided procedures to relieve shoulder pain that often follows a stroke. One uses pulsed radiofrequency to modulate nerve activity, while the other uses a phenol injection to temporarily block nerves. The study includes adults with post-stroke hemiplegic shoulder pain and aims to see which approach better reduces pain, improves shoulder function and quality of life, and has fewer side effects over six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pulsed radiofrequency neuromodulation or phenol neurolysis, both delivered via ultrasound guidance to shoulder nerves
What this could lead to
If successful, this could point toward a better, longer-lasting way to relieve post-stroke shoulder pain and improve arm function and quality of life.
What could go wrong
This is a relatively small trial, and results may not apply to everyone. Both procedures carry risks like pain, bleeding, or nerve damage, and the phenol injection may cause more side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. History of ischemic or hemorrhagic stroke confirmed clinically and/or by neuroimaging when available. Post-stroke shoulder pain on the hemiplegic side with VAS pain intensity \>=4/10 during rest, passive movement or functional use. Spasticity of target shoulder-girdle muscles with MAS score \>=2. Stable medical condition allowing outpatient or inpatient interventional procedure. Ability to provide written informed consent; if the patient has a communication impairment, consent will follow institutional ethics-approved procedures involving legally authorized representatives when appropriate. Expected ability to attend scheduled follow-up visits through 6 months Exclusion Criteria: * Previous radiofrequency treatment or phenol neurolysis to the affected shoulder within the previous 6 months. Botulinum toxin injection to the target shoulder muscles within the previous 3-6 months. Shoulder fracture, dislocation or rotator cuff tear requiring surgery. Active infection at the injection site. Known allergy or contraindication to phenol, local anesthetic, antiseptic solution or other procedure-related medication. Coagulopathy, platelet disorder or anticoagulant/antiplatelet treatment that cannot be safely managed according to local anesthesia/interventional-pain policy. Severe uncontrolled medical illness, unstable cardiopulmonary disease, uncontrolled diabetes with active infection risk, or any condition judged by investigators to increase procedural risk. Severe cognitive, behavioral, or communication impairment preventing reliable pain/outcome assessment unless a validated caregiver-assisted assessment approach is approved by the ethics committee. Pregnancy or lactation, when applicable, because of procedural medication exposure and safety monitoring requirements. Concurrent participation in another interventional trial that may affect shoulder pain, tone or function.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-stroke hemiplegic shoulder pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.